![1]()
News
Two swings, two misses with colchicine, Vascepa in COVID-19
September 1, 2021
The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.
![1]()
News
EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF
August 31, 2021
The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.
![1]()
News
Dapagliflozin in HFrEF may cut arrhythmias, sudden death: DAPA-HF
August 27, 2021
Response to the positive findings was tempered, however, by the post hoc nature of the analysis, choice of primary outcome, and inconsistencies between key subgroups.
![1]()
News
ICMs detect serious arrhythmias in high-risk post-MI patients: SMART-MI
August 27, 2021
In patients with modestly reduced left ventricular ejection fraction after MI, implantable monitors detect many times more arrhythmias than usual care, the SMART-MI trial showed.
![1]()
News
Optimizing screening for asymptomatic Afib
August 27, 2021
How can we optimize screening for patients with asymptomatic atrial fibrillation (Afib)?
![1]()
News
EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough
August 27, 2021
Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.
![1]()
News
ACE-I or ARB therapy in patients with low eGFR
August 26, 2021
Is it safe to continue angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) therapy in patients whose estimated glomerular filtration rate (eGFR) has decreased to below 30 mL/min per 1.73 m2?
![1]()
News
SGLT2 inhibitor use rising in patients with DKD
August 23, 2021
Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.
![1]()
News
Apixaban more effective, safer than rivaroxaban for Afib patients
August 23, 2021
Is apixaban more effective and safer than rivaroxaban in patients with atrial fibrillation?
News
Empagliflozin gets HFrEF approval from FDA
August 19, 2021
The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.
